EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors

Liangqun Huang, Megan Gish iD, James Boehlke, Ryan H Jeep, Chaoping Chen

Viruses · 2024

DOI: 10.3390/v16081218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Liangqun Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Coronavirus 3C Proteases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH-NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 main protease (Mpro) is initially synthesized as part of polyprotein precursors that undergo autoproteolysis to release the free mature Mpro. To investigate the autoprocessing mechanism in transfected mammalian cells, we examined several fusion precursors, with the mature SARS-CoV-2 Mpro along with the flanking amino acids (to keep the native substrate sequences) sandwiched between different tags. Our analyses revealed differential proteolysis kinetics at the N- and C-terminal cleavage sites. Particularly, N-terminal processing is differentially influenced by various upstream fusion tags (GST, sGST, CD63, and Nsp4) and amino acid variations at the N-terminal P1 position, suggesting that precursor catalysis is flexible and subject to complex regulation. Mutating Q to E at the N-terminal P1 position altered both precursor catalysis and the properties of the released Mpro. Interestingly, the wild-type precursors exhibited different enzymatic activities compared to those of the released Mpro, displaying much lower susceptibility to known inhibitors targeting the mature form. These findings suggest the precursors as alternative targets for antiviral development. Accordingly, we developed and validated a high-throughput screening (HTS)-compatible platform for functional screening of compounds targeting either the N-terminal processing of the SARS-CoV-2 Mpro precursor autoprocessing or the released mature Mpro through different mechanisms of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCoronavirus 3C ProteasesHumansProteolysisHEK293 CellsCOVID-19 Drug TreatmentCOVID-19

Stichwörter der Autor:innen

3C-like proteaseNsp5SARS-CoV-2autoproteolysiscatalysis flexibilityglycosylationmain proteaseprecursor autoprocessingprotease precursor

Substanzen

Antiviral AgentsCoronavirus 3C Proteases

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.

ORCID-Profile: Megan Gish

Förderung

  • NIAID NIH HHS
  • NIH-NIAID

Zitieren

APA

Huang, L., Gish, M., Boehlke, J., Jeep, R. H., & Chen, C. (2024). Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors. Viruses. https://doi.org/10.3390/v16081218

Vancouver

Huang L, Gish M, Boehlke J, Jeep RH, Chen C. Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors. Viruses. 2024. doi:10.3390/v16081218

BibTeX
@article{Huang2024,
  author = {Huang, Liangqun and Gish, Megan and Boehlke, James and Jeep, Ryan H and Chen, Chaoping},
  title = {Assay Development and Validation for Innovative Antiviral Development Targeting the N-Terminal Autoprocessing of SARS-CoV-2 Main Protease Precursors},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16081218}
}
Kostenlos starten →